Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

Authors


Address correspondence and reprint requests to Cris S. Constantinescu, Division of Clinical Neurology, University of Nottingham, Queen’s Medical Centre, C Floor South Block, Nottingham NG7 2UH, UK.
E-mail: cris.constantinescu@nottingham.ac.uk

Abstract

J. Neurochem. (2010) 115, 829–844.

Abstract

The precise aetio-pathology of multiple sclerosis remains elusive. However, important recent advances have been made and several therapies have been licensed for clinical use. Many of these were developed, validated or tested in the animal model, experimental autoimmune encephalomyelitis (EAE). This systematic review aims to assess whether the current disease modifying treatments and those that are the closest to the clinic are justified on the basis of the results of EAE studies. We discuss some aspects of the utility and caveats of EAE as a model for multiple sclerosis drug development.

Ancillary